Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Transition Therapeutics Inc    TTH   CA8937162094

 SummaryChartsNewsCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
08/22/2016 08/23/2016 08/25/2016 08/26/2016 08/29/2016 Date
2.06 2.02 2.02 1.92 1.93 Last
400 700 500 180 7200 Volume
+0.98% -1.94% 0.00% -4.95% +0.52% Change
Company
Transition Therapeutics, Inc. develops novel therapeutics for disease indications.It operates through research and development of therapeutic agents segment.The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome.Its metabolic drug candidate... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Latest news on TRANSITION THERAPEUTICS IN
2016 TRANSITION THERAPEUTICS : Announces Special Shareholder Meeting Voting Results I..
2016 TRANSITION THERAPEUTICS : Receives Notification From NASDAQ
2016 TRANSITION THERAPEUTICS : Announces Third Quarter Fiscal 2016 Financial Results
2016 TRANSITION THERAPEUTICS TO HOLD CONF : 30 p.m. est
2016 TRANSITION THERAPEUTICS : Provides Update on Type 2 Diabetes Drug Candidate TT40..
2016 TRANSITION THERAPEUTICS : Receives Notification From NASDAQ
2016 TRANSITION THERAPEUTICS : to Present at the 36th Annual Cowen Healthcare Confere..
2016 TRANSITION THERAPEUTICS : Announces Second Quarter Fiscal 2016 Financial Results
2016 TRANSITION THERAPEUTICS : to Hold Conference Call on Second Quarter Fiscal 2016 ..
2016 TRANSITION THERAPEUTICS : Announces Top Line Phase 2 Clinical Study Results of D..
More news
Sector news : Biopharmaceuticals
03:42p NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Transition Therapeutics shareholders back OPKO merger
2016 OPKO buys Transition Therapeutics in all-stock deal
2016 Bayer expands development program for prostate cancer candidate BAY-1841788 w..
2016 Transition Therapeutics' (TTHI) CEO Chip Brewer on Q3 2016 Results - Earnings..
2016 Transition Therapeutics reports FQ3 results
Advertisement
Chart TRANSITION THERAPEUTICS IN
Duration : Period :
Transition Therapeutics In Technical Analysis Chart | TTH | CA8937162094 | 4-Traders
Full-screen chart
Managers
NameTitle
Tony F. Cruz Chairman & Chief Executive Officer
Carl Damiani President & Chief Operating Officer
Nicole Rusaw-George Chief Financial Officer
Aleksandra Pastrak VP-Clinical Development & Medical Officer
Michael Richard Dwyer Ashton Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TRANSITION THERAPEUTIC..0.00%0
BIOGEN INC5.39%59 475
CSL LIMITED21.87%42 756
ALEXION PHARMACEUTICAL..-1.71%27 012
BIOMARIN PHARMACEUTICA..4.83%15 012
GRIFOLS SA14.67%14 629
More Results